Stoke Therapeutics (NASDAQ:STOK) reported quarterly losses of $(0.93) per share which missed the analyst consensus estimate of $(0.80) by 16.25 percent. This is a 132.5 percent decrease over losses of $(0.40) per share from the same period last year. The company reported quarterly sales of $9.325 million which beat the analyst consensus estimate of $6.044 million by 54.27 percent. This is a 32.51 percent decrease over sales of $13.817 million the same period last year.